Want to see EVAX full AI Analyst Report?
EVAX Stock Chart & Stats
$2.96
-$0.09(-2.95%)
At close: 4:00 PM EDT
$2.96
-$0.09(-2.95%)
Day’s Range― - ―
52-Week Range$2.45 - $12.15
Previous Close$2.96
Volume3.35K
Average Volume (3M)20.50K
Market Cap
$23.52M
Enterprise Value$15.85
Total Cash (Recent Filing)$18.44M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Aug 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding8,340,215
10 Day Avg. Volume13,703
30 Day Avg. Volume20,495
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.79
Price to Sales (P/S)4.06
P/FCF Ratio-4.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.25Price Target Upside280.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$5.27M
Bulls Say, Bears Say
Bulls Say
Clinically Validated AI‑Immunology PlatformClinical validation across three oncology trials materially reduces platform technical risk and supports durable differentiation. That evidence strengthens licensing and partnership prospects, increases the likelihood of technology transfer across indications, and underpins a platform-led business model over the next 2–6 months and beyond.
Strong EVX‑01 Immunogenicity And Clinical SignalsRobust translational and clinical response metrics for EVX‑01 improve the program's de‑risking profile and support regulatory dialogue. Durable clinical readthroughs can attract strategic partners for late‑stage development and commercialization, reducing execution risk and strengthening long‑term upside from a successful vaccine asset.
Scalability Into Low‑mutational Tumors (GBM)Demonstrated scalability into glioblastoma and the use of ERV antigens expands addressable markets beyond high‑mutation tumors. This capability supports both personalized and potentially broader off‑the‑shelf approaches, enhancing long‑term commercial versatility and partner interest across hard‑to‑treat indications.
Bears Say
Finite Cash Runway Into H2 2027A runway that extends only into H2 2027 without assumed partnerships forces near‑term financing or dealmaking. This constraint can delay programs, compress negotiating leverage with potential partners, and raise the probability of dilution or program prioritization decisions that affect long‑term growth and execution continuity.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow means the company cannot self‑fund advancement of multiple programs. Structural cash burn increases reliance on external capital or partnerships, which can slow development timelines, reduce optionality for pipeline expansion, and create recurring refinancing and dilution risks over the medium term.
Partnerships Not Finalized; BD Discussions OngoingActive but unclosed business development leaves funding and program execution uncertain. Combined with shareholder authorization to issue warrants and convertible loans, the lack of finalized partners raises structural dilution and refinancing risk and may weaken bargaining power when negotiating term sheets for strategic collaborations.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech A/S Adr’s price range in the past 12 months?
Evaxion Biotech A/S Adr lowest stock price was $2.45 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech A/S Adr’s market cap?
Evaxion Biotech A/S Adr’s market cap is $23.52M.
When is Evaxion Biotech A/S Adr’s upcoming earnings report date?
Evaxion Biotech A/S Adr’s upcoming earnings report date is Aug 20, 2026 which is in 18 days.
How were Evaxion Biotech A/S Adr’s earnings last quarter?
Evaxion Biotech A/S Adr released its earnings results on May 07, 2026. The company reported -$0.01 earnings per share for the quarter, the consensus estimate of -$0.01 by $0.
Is Evaxion Biotech A/S Adr overvalued?
According to Wall Street analysts Evaxion Biotech A/S Adr’s price is currently Undervalued.
Does Evaxion Biotech A/S Adr pay dividends?
Evaxion Biotech A/S Adr does not currently pay dividends.
What is Evaxion Biotech A/S Adr’s EPS estimate?
Evaxion Biotech A/S Adr’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech A/S Adr have?
Evaxion Biotech A/S Adr has 8,340,215 shares outstanding.
What happened to Evaxion Biotech A/S Adr’s price movement after its last earnings report?
Evaxion Biotech A/S Adr reported an EPS of -$0.01 in its last earnings report, expectations of -$0.01. Following the earnings report the stock price went down -7.71%.
Which hedge fund is a major shareholder of Evaxion Biotech A/S Adr?
Currently, no hedge funds are holding shares in EVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evaxion Biotech A/S Adr
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
EVAX Company Deck
EVAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong R&D and platform momentum, highlighted by robust EVX-01 immunogenicity (86% immunogenicity and de novo response rates), supportive clinical signals (75% overall response rate previously reported), platform scalability into GBM (fully personalized designs for 24/24 cases, with 21/24 designs including both neoantigen and ERV components), and novel vaccine concepts (polio work with The Gates Foundation). The company also reinforced disciplined financial management and confirmed cash runway into H2 2027. Key risks discussed include a finite cash runway, a Q1 net loss of USD 3.6M and reduced equity, and the absence of finalized partnerships to extend funding or accelerate certain programs. On balance, the positive clinical and platform developments materially outweigh the financial and partnership uncertainties, though the latter remain important near-term considerations.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$11.25
▲(280.07% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.67% Other Institutional Investors
99.32% Public Companies and
Individual Investors